Please login to the form below

Not currently logged in

Lisocabtagene maraleucel

This page shows the latest Lisocabtagene maraleucel news and features for those working in and with pharma, biotech and healthcare.

BMS reports strong growth as its Q3 results beat predictions

BMS reports strong growth as its Q3 results beat predictions

up from $24m in Q2, while Breyanzi (lisocabtagene maraleucel), launched this year in lymphoma, had $30m in sales, up from $17m earlier in the year.

Latest news

More from news
Approximately 1 fully matching, plus 17 partially matching documents found.

Latest Intelligence

  • Cortellis Drugs to Watch in 2020 report Cortellis Drugs to Watch in 2020 report

    Liso-cel (lisocabtagene maraleucel, JCAR-017) is an immunotherapy comprised of autologous T cells genetically modified (via lentiviral vector) to express an anti-CD19 chimeric antigen receptor (CAR).

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Subscribe to our email news alerts

Featured jobs


Add my company
Jet Off with Maloff Protect

Latest intelligence

Five big changes in the healthcare comms landscape
The world of healthcare has changed very greatly in the five years since The Difference Collective launched. Our agile model and talented team have enabled us to keep pace with...
Early communications in Pharma: How effective pre-approval comms delivers launch success
What communications are required for a successful launch...
Our Top 5 Pharma Picks From Cannes Lions
Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....